Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation

Tejus Anantharamu, Sushil Sharma, Ajay Kumar Gupta, Navdeep Dahiya, Dick B Singh Brashier, Ashok Kumar Sharma, Tejus Anantharamu, Sushil Sharma, Ajay Kumar Gupta, Navdeep Dahiya, Dick B Singh Brashier, Ashok Kumar Sharma

Abstract

Opioid-induced constipation (OIC) is one of the most troublesome and the most common effects of opioid use leading to deterioration in quality of life of the patients and also has potentially deleterious repercussions on adherence and compliance to opioid therapy. With the current guidelines advocating liberal use of opioids by physicians even for non-cancer chronic pain, the situation is further complicated as these individuals are not undergoing palliative care and hence there cannot be any justification to subject these patients to the severe constipation brought on by opioid therapy which is no less debilitating than the chronic pain. The aim in these patients is to prevent the opioid-induced constipation but at the same time allow the analgesic activity of opioids. Many drugs have been used with limited success but the most specific among them were the peripherally acting mu opioid receptor antagonists (PAMORA). Methylnaltrexone and alvimopan were the early drugs in this group but were not approved for oral use in OIC. However naloxegol, the latest PAMORA has been very recently approved as the first oral drug for OIC. This article gives an overview of OIC, its current management and more specifically the development and approval of naloxegol, including pharmacokinetics, details of various clinical trials, adverse effects and its current status for the management of OIC.

Keywords: Naloxegol; opioid-induced constipation; peripherally acting mu opioid receptor antagonists.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Gehdoo RP. Cancer pain management. Indian J Anaesth. 2006;50:375–90.
    1. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Mernil JO, Sullivan MD, et al. Opioid prescription for chronic pain and overdose: A cohort study. Ann Intern Med. 2010;152:85–92.
    1. Camilleri M. Opioid-induced constipation: Challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106:835–42. quiz 843.
    1. Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: Pathophysiology, clinical consequences, and management. Gastroenterol Res Pract 2014. 2014 141737.
    1. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009;155:11–7.
    1. Chung HH. The novel role of opioid -receptors in gastroenterology. J Gastroenterol Hepatol Res. 2013;2:614–7.
    1. Aurilio C, Pace MC, Pota V, Sansone P. Opioid induced constipation. In: Smith AC, editor. Constipation-Causes, Diagnosis and Treatment. Croatia: InTech; 2012. pp. 81–8.
    1. Clemens KE, Klaschik E. Managing opioid-induced constipation in advanced illness: Focus on methylnaltrexone bromide. Ther Clin Risk Manag. 2010;6:77–82.
    1. FDA Okays Naloxegol (Movantik) in Opioid-Induced Constipation. [Last accessed on 2014 Sep 24]. Available from: .
    1. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of Naloxegol in patients with opioid-induced constipation. Pain. 2013;154:1542–50.
    1. Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of Naloxegol. J Clin Pharmacol. 2014;54:1375–82.
    1. Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014;7:345–58.
    1. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with non-cancer pain. N Engl J Med. 2014;370:2387–96.
    1. Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: The long-term safety and tolerability of Naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40:771–9.
    1. Gottfridsson C, Carlson G, Lappalainen J, Sostek M. Evaluation of the effect of naloxegol on cardiac repolarization: A randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Clin Ther. 2013;35:1876–83.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere